ASCENTAGE PHARM. DL-0001
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibit… Read more
Market Cap & Net Worth: ASCENTAGE PHARM. DL-0001 (36X)
ASCENTAGE PHARM. DL-0001 (F:36X) has a market capitalization of $1.95 Billion (€1.90 Billion) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #6114 globally and #647 in its home market, demonstrating a 10.87% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ASCENTAGE PHARM. DL-0001's stock price €5.10 by its total outstanding shares 371853475 (371.85 Million).
ASCENTAGE PHARM. DL-0001 Market Cap History: 2019 to 2026
ASCENTAGE PHARM. DL-0001's market capitalization history from 2019 to 2026. Data shows growth from $1.25 Billion to $1.95 Billion (6.50% CAGR).
ASCENTAGE PHARM. DL-0001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ASCENTAGE PHARM. DL-0001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 36X by Market Capitalization
Companies near ASCENTAGE PHARM. DL-0001 in the global market cap rankings as of March 19, 2026.
Key companies related to ASCENTAGE PHARM. DL-0001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
ASCENTAGE PHARM. DL-0001 Historical Marketcap From 2019 to 2026
Between 2019 and today, ASCENTAGE PHARM. DL-0001's market cap moved from $1.25 Billion to $ 1.95 Billion, with a yearly change of 6.50%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.95 Billion | -6.42% |
| 2025 | €2.08 Billion | -2.68% |
| 2024 | €2.14 Billion | +97.18% |
| 2023 | €1.08 Billion | -4.05% |
| 2022 | €1.13 Billion | +4.23% |
| 2021 | €1.08 Billion | -22.83% |
| 2020 | €1.40 Billion | +12.54% |
| 2019 | €1.25 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of ASCENTAGE PHARM. DL-0001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.95 Billion USD |
| MoneyControl | $1.95 Billion USD |
| MarketWatch | $1.95 Billion USD |
| marketcap.company | $1.95 Billion USD |
| Reuters | $1.95 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.